Gabapentin Global Market Report 2026

Gabapentin is a prescription medication primarily used to manage nerve pain, epilepsy, and restless legs syndrome. It works by targeting nerve signals and brain chemicals to control seizures and relieve nerve pain, including pain caused by shingles and diabetic neuropathy. Gabapentin helps stabilize brain activity and reduce abnormal nerve excitability.

The main types of gabapentin are generic and branded. Generic versions contain the same active ingredients and dosages as branded drugs, offering a more affordable but equally effective alternative. Gabapentin is available in various dosage forms, including tablets, capsules, and oral solutions, and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Its applications include epilepsy, neuropathic pain, restless legs syndrome, and other conditions.

Tariffs have influenced the gabapentin market by raising the cost of active pharmaceutical ingredients, capsule shells, and packaging materials. Generic and extended-release formulations are most affected, particularly in Asia-Pacific and North America where large volumes of gabapentin APIs are imported. Retail and hospital pharmacies face cost increases. Positively, tariffs are promoting domestic API manufacturing and generic drug production.

The gabapentin market research report is one of a series of new reports from The Business Research Company that provides gabapentin market statistics, including gabapentin industry global market size, regional shares, competitors with a gabapentin market share, detailed gabapentin market segments, market trends and opportunities, and any further data you may need to thrive in the gabapentin industry. This gabapentin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gabapentin market size has grown strongly in recent years. It will grow from $3.01 billion in 2025 to $3.26 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to epilepsy treatment adoption, neuropathic pain prevalence, generic drug availability, physician prescribing patterns, chronic disease burden.

The gabapentin market size is expected to see strong growth in the next few years. It will grow to $4.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to aging population, diabetic neuropathy growth, generic penetration, outpatient pain management, telemedicine prescriptions. Major trends in the forecast period include rising use in neuropathic pain management, increased demand for generic formulations, expansion of chronic pain treatment programs, growth of oral solid dosage forms, increased prescriptions for neurological disorders.

The increasing prevalence of epilepsy is expected to drive the growth of the gabapentin market in the coming years. Epilepsy is a neurological disorder characterized by recurrent seizures caused by irregular electrical activity in the brain. The rising number of epilepsy cases is primarily driven by the growing elderly population, as aging increases susceptibility to neurological conditions that trigger seizures. Gabapentin manages epilepsy by stabilizing abnormal nerve activity in the brain and reducing seizure-inducing signals. It targets calcium channels to help prevent seizure occurrence. For instance, in February 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 50 million people globally have epilepsy, with nearly 80% residing in low- and middle-income countries. Up to 70% of these patients could live seizure-free with proper diagnosis and treatment. Each year, an estimated 5 million people are newly diagnosed with epilepsy worldwide; incidence rates are around 49 per 100,000 in high-income countries and can reach 139 per 100,000 in low- and middle-income countries. Therefore, the increasing prevalence of epilepsy is driving the growth of the gabapentin market.

Major companies operating in the gabapentin market are focusing on developing advanced formulations, such as bioequivalent tablets, to enhance therapeutic efficacy and expand treatment options for neurological disorders. Bioequivalent tablets are generic medications that deliver the same dose of the active ingredient into the bloodstream at the same rate and extent as branded versions, ensuring comparable safety and effectiveness. For instance, in March 2024, Strides Pharma Science Limited, an India-based pharmaceutical company, launched Gabapentin Tablets USP in 600 mg and 800 mg strengths, receiving approval from the United States Food & Drug Administration (USFDA) to expand its neurology portfolio in the US. These tablets feature enhanced bioavailability, precise dosing, and patient-friendly administration, allowing for consistent therapeutic outcomes, improved symptom control, and greater convenience for long-term therapy. Gabapentin Tablets USP, 600 mg, provide effective management of neurological conditions such as neuropathic pain and partial seizures through reliable dosing and proven clinical efficacy.

In September 2023, Adalvo, a Malta-based pharmaceutical company, collaborated with Lotus Pharmaceutical to enhance access to innovative neurological care. The partnership aims to launch Gabapentin ER in South Korea, offering a convenient once-daily treatment for postherpetic neuralgia, addressing unmet needs, and expanding market presence in neurology. Lotus Pharmaceutical is a Taiwan-based manufacturer specializing in gabapentin extended-release tablets.

Major companies operating in the gabapentin market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan Inc., Apotex Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Ipca Laboratories Private Limited, Granules India Limited, Medley Pharmaceuticals Limited, Wockhardt Limited, Epic Pharma LLC, Healing Pharma India Pvt. Ltd., Rochem International Inc., Accord Healthcare Limited, Strides Pharma Science Limited, Ascend Laboratories LLC

North America was the largest region in the gabapentin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gabapentin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gabapentin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gabapentin market consists of sales of gabapentin immediate-release, gabapentin extended-release, and oral solution. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gabapentin Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses gabapentin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gabapentin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gabapentin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Generic; Branded
• 2) By Dosage Form: Tablet; Capsule; Oral Solution
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 4) By Application: Epilepsy; Neuropathic Pain; Restless Legs Syndrome; Other Applications
• Subsegments:
• 1) By Generic: Gabapentin Immediate Release (IR); Gabapentin Extended Release (ER); Gabapentin Capsules; Gabapentin Tablets; Gabapentin Oral Solution
• 2) By Branded: Neurontin; Gralise; Horizant; Other Branded Formulations
• Companies Mentioned: Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Mylan Inc.; Apotex Inc.; Sun Pharmaceutical Industries Ltd.; Aurobindo Pharma Limited; Cipla Limited; Lupin Limited; Zydus Lifesciences Limited; Glenmark Pharmaceuticals Limited; Torrent Pharmaceuticals Ltd.; Ipca Laboratories Private Limited; Granules India Limited; Medley Pharmaceuticals Limited; Wockhardt Limited; Epic Pharma LLC; Healing Pharma India Pvt. Ltd.; Rochem International Inc.; Accord Healthcare Limited; Strides Pharma Science Limited; Ascend Laboratories LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.